Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
Launched by BIOGEN · Mar 5, 2003
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Male and female patients at least 18 years of age with at least a six-month history of Crohn's disease and who are currently receiving Remicade and are not in remission (CDAI greater than/equal to 150)
- • Women must not be breastfeeding or pregnant, and must not become pregnant during the study.
About Biogen
Biogen is a leading biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. With a strong focus on research and development, Biogen leverages advanced science and cutting-edge technology to address the unmet needs of patients suffering from conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company is committed to advancing the understanding of the underlying biology of these diseases and is actively engaged in clinical trials to evaluate new treatment options, aiming to improve patient outcomes and enhance quality of life. With a global presence and a robust pipeline of therapies, Biogen is at the forefront of innovation in the biopharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Butte, Montana, United States
Atlanta, Georgia, United States
Raleigh, North Carolina, United States
Great Neck, New York, United States
Seattle, Washington, United States
Lexington, Kentucky, United States
Gainesville, Florida, United States
Jacksonville, Florida, United States
Asheville, North Carolina, United States
Rocky Mount, North Carolina, United States
Columbia, South Carolina, United States
Memphis, Tennessee, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Danville, Virginia, United States
Virginia Beach, Virginia, United States
Tacoma, Washington, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials